measurement of fibrosis marker xylosyltransferase I activity by HPLC electrospray ionization tandem mass spectrometry. The simple and robust LC-MS/MS assay permits the rapid and accurate determination of XT-I activity in human serum
monitoring of the seminal plasma for enzyme activity is proposed to be an advantegeous additional biochemical parameter to improve in vitro fertilization methods, because the activity is reduced in seminal plasma of infertile men
serum xylosyltransferase activity is a biochemical marker for the assessment of disease activity in systemic sclerosis and for the diagnosis of fibrotic remodeling processes. Sequence variations in the XT-I and XT-II coding genes are identified as risk factors for diabetic nephropathy, osteoarthritis or pseudoxanthoma elasticum. Important role of the xylosyltransferases as disease modifiers in pathologies which are characterized by an altered proteoglycan metabolism
serum xylosyltransferase I, the novel fibrosis marker, may be useful for the assessment of extracellular matrix alterations and disease activity in Pseudoxanthoma elasticum
serum xylosyltransferase activity is a biochemical marker for the assessment of disease activity in systemic sclerosis and for the diagnosis of fibrotic remodeling processes, sequence variations in the XT-I coding gene are identified as risk factors for diabetic nephropathy, osteoarthritis or pseudoxanthoma elasticum
serum xylosyltransferase activity is a biochemical marker for the assessment of disease activity in systemic sclerosis and for the diagnosis of fibrotic remodeling processes, sequence variations in the XT-II coding gene are identified as risk factors for diabetic nephropathy, osteoarthritis or pseudoxanthoma elasticum
ways of modulating the XYLT1 gene expression, especially in the development of therapeutic strategies for the treatment of fibrotic remodeling processes or cartilage repair